Ranbaxy shares slump 5% mcap down Rs 1,072 crore
Shares of Ranbaxy Laboratories slumped nearly 5 percent today as the company sued USFDA over revoking an approval to sell generic versions of two drugs -- digestive disorder medicine Nexium and anti-viral Valcyte-- in the US market.
Nov 19, 2014, 17:26 PM IST